Health Partners Plans

HEALTH PARTNERS PLANS
2023 PRIOR AUTHORIZATION REQUEST FORM

Nurtec

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
HPP HPP Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Patient Primary Phone:	NPI:	*PA PROMISe ID:*
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Line of Business: ð Medicaid ð CHIP	*Specialty Pharmacy (if applicable):*	
Drug Name:	**Strength:**	
Quantity:	**Refills:**	
Directions:		
Diagnosis Code:	**Diagnosis:**	
HPP's maximum approval time is 12 months but may be less depending on the drug.		

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is the patient prescribed a dose and frequency that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

☐ Yes ☐ No

Q2. Does the patient have a history of contraindication to the prescribed medication?

☐ Yes ☐ No

Q3. Is this a request for renewal of Nurtec for acute treatment of migraine?

☐ Yes ☐ No

Q4. Is this a request for renewal of Nurtec for preventive treatment of migraine?

☐ Yes ☐ No

Q5. Is the requested drug being prescribed for the treatment of a diagnosis that is indicated in the Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication?

☐ Yes ☐ No

Q6. Is the requested drug age-appropriate for the patient according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

☐ Yes ☐ No

Health Partners Plans

HEALTH PARTNERS PLANS
2023 PRIOR AUTHORIZATION REQUEST FORM

Nurtec

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:

Q7. Is the requested medication being used for the acute treatment of migraine or for the preventive treatment of migraine?

☐ Yes ☐ No

Q8. For the acute treatment of migraine, does the patient have a diagnosis confirmed according to the current International Headache Society Classification of Headache Disorders?

☐ Yes ☐ No

Q9. For the acute treatment of migraine, does the patient have BOTH of the following: a. ONE of the following:
i. A history of therapeutic failure of at least two (5-HT 1B/1D) receptor agonists (triptans) OR ii. Has a contraindication or intolerance to the preferred triptans b. If currently using a different gepant, ONE of the following: i. Will discontinue use of that gepant prior to starting the requested gepant, ii. Has a medical reason for concomitant use of both gepants that is supported by peer-reviewed literature or national treatment guidelines.

☐ Yes ☐ No

Q10. For acute treatment of migraine, does the quantity exceeds the quantity limit in place?

☐ Yes ☐ No

Q11. For a quantity exceeding the quantity limit in place, does the request meet ALL of the following: a. All criteria guidelines are met, b. The drug is being prescribed by a neurologist or headache specialist who is certified in headache medicine by the UCNS, c. ONE of the following: i. The beneficiary is using the requested medication in addition to at least one medication for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody), ii. The beneficiary has a history of therapeutic failure, contraindication, or intolerance to all preventive migraine medications recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society) d. The patient was evaluated for the overuse of abortive medications, including opioids.

☐ Yes ☐ No

Q12. For preventive treatment of migraine, is the medication being prescribed by or in consultation with one of the following: a. A neurologist, b. A headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS).

☐ Yes ☐ No

Health Partners Plans

HEALTH PARTNERS PLANS
2023 PRIOR AUTHORIZATION REQUEST FORM

Nurtec

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:

Q13. Is documentation attached showing baseline average number of migraine days and headache days per month?

☐ Yes ☐ No

Q14. Has the patient averaged four or more migraine days per month over the previous three months?

☐ Yes ☐ No

Q15. Does the patient have a diagnosis of migraine with or without aura confirmed according to the current International Headache Society Classification of Headache Disorders?

☐ Yes ☐ No

Q16. Does the patient have a history of therapeutic failure, contraindication, or intolerance of at least one preventive medication from two of the following three classes: a. Beta-blockers (e.g., metoprolol, propranolol, timolol), b. Antidepressants (e.g., amitriptyline, venlafaxine), c. Anticonvulsants (e.g., topiramate, valproic acid, divalproex)

☐ Yes ☐ No

Q17. Is the patient currently using a different gepant?

☐ Yes ☐ No

Q18. Does the patient meet ONE of the following: a. Will discontinue use of that gepant prior to starting the requested gepant, b. Has a medical reason for concomitant use of both gepants that is supported by peer-reviewed literature or national treatment guidelines.

☐ Yes ☐ No

Q19. Does the patient have a documented history of therapeutic failure, contraindication, or intolerance to the preferred CGRP monoclonal antibodies (mAbs) approved or medically accepted for the beneficiary's indication?

☐ Yes ☐ No

Q20. For acute treatment of migraine, is documentation attached showing improvement in headache pain, symptoms, or duration?

☐ Yes ☐ No

Q21. For acute treatment of migraine, does the quantity exceeds the quantity limit in place?

☐ Yes ☐ No

Health Partners Plans

HEALTH PARTNERS PLANS
2023 PRIOR AUTHORIZATION REQUEST FORM

Nurtec

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:

Q22. For a quantity exceeding the quantity limit in place, does the request meet ALL of the following: a. All criteria guidelines are met, b. The drug is being prescribed by a neurologist or headache specialist who is certified in headache medicine by the UCNS, c. ONE of the following: i. The beneficiary is using the requested medication in addition to at least one medication for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody), ii. The beneficiary has a history of therapeutic failure, contraindication, or intolerance to all preventive migraine medications recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society), d. Documentation of an evaluation for the overuse of abortive medications, including opioids.

☐ Yes ☐ No

Q23. For preventive treatment of migraine, is the medication being prescribed by or in consultation with one of the following: a. A neurologist, b. A headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS).

☐ Yes ☐ No

Q24. Has the patient experienced ONE of the following: a. Has a reduction in the average number of migraine days or headache days per month from baseline, b. Experienced a decrease in severity or duration of migraines from baseline.

☐ Yes ☐ No

Q25. Does the patient have a documented history of therapeutic failure, contraindication, or intolerance to the preferred CGRP monoclonal antibodies (mAbs) approved or medically accepted for the beneficiary's indication?

☐ Yes ☐ No

Q26. Additional Information:

_____ _____

Prescriber Signature Date

Updated for 2023